New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Xalud Therapeutics is raising $30,000,001.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Diem Nguyen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xalud Therapeutics
Over 300 million people worldwide suffer from chronic inflammatory diseases. There is a large unmet need for treatments for chronic inflammatory disease that are efficacious and safe. Xalud Therapeutics is developing a non-viral gene therapy targeting immune modulation. Our mission is to harness the power of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. A healthy, strong body lives in a state of equilibrium. Every day, it detects potential signals of injury or chronic disease progression and naturally restores itself by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators. Unfortunately when the body’s immune system is unbalanced, inflammation can flare and persist over long periods of time. This results in a myriad of diseases and associated symptoms, including chronic, debilitating pain that prevents millions of people from living healthy productive lives. Xalud Therapeutics aims to break this cycle of chronic, pathologic inflammation. Instead of masking symptoms like traditional pain drugs, we help the body to restore the critical balance of inflammatory and restorative pathways by adding back one of the body’s own natural defenses to increase important anti-inflammatory signals.

To learn more about Xalud Therapeutics, visit http://www.xaludthera.com/

Contact:
Diem Nguyen, Chief Executive Officer
434-980-8117
https://www.linkedin.com/in/diem-nguyen-11a3702/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved